

DAFTAR PUSTAKA

- Acevedo, M. L. *et al.* (2021) 'Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda', *medRxiv*.
- Afelt, A. *et al.* (2018) 'Bats, bat-borne viruses, and environmental changes', *Bats. London, UK: IntechOpen*, pp. 113–132.
- Al-Qahtani, M. *et al.* (2021) 'The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects', *International Journal of Infectious Diseases*, 102, pp. 285–288.
- Atalan, A. (2020) 'Is the lockdown important to prevent the COVID-19 pandemic? Effects on psychology, environment and economy-perspective', *Annals of medicine and surgery*, 56, pp. 38–42.
- Bastard, J. P. *et al.* (2002) 'RNA isolation and purification methods', in *Annales de biologie clinique*, pp. 513–523.
- Bokulich, N. A. *et al.* (2013) 'Quality-filtering vastly improves diversity estimates from Illumina amplicon sequencing', *Nature methods*, 10(1), pp. 57–59.
- Bontempi, E. (2021) 'The europe second wave of COVID-19 infection and the Italy "strange" situation', *Environmental Research*, 193, p. 110476.
- Borak, J. (2020) 'Airborne transmission of COVID-19'. Oxford University Press UK.
- Brittain-Long, R. *et al.* (2008) 'Multiplex real-time PCR for detection of respiratory tract infections', *Journal of Clinical Virology*, 41(1), pp. 53–56.
- Bustin, S. A. and Mueller, R. (2005) 'Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis', *Clinical Science*, 109(4), pp. 365–379.
- Casella, M. *et al.* (2021) 'Features, evaluation, and treatment of coronavirus (COVID-19)', *Statpearls [internet]*.
- Cauchemez, S. *et al.* (2014) 'Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility', *The Lancet infectious diseases*, 14(1), pp. 50–56.
- Chan, J. F.-W. *et al.* (2013) 'Interspecies transmission and emergence of novel viruses: lessons from bats and birds', *Trends in microbiology*, 21(10), pp. 544–555.
- Chen, N. *et al.* (2020) 'Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study', *The*

lancet, 395(10223), pp. 507–513.

Cherian, S. *et al.* (2021) ‘Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India’, *BioRxiv*.

Ciceri, F. *et al.* (2020) ‘Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis’, *Critical care and resuscitation*, 22(2), p. 95.

Conti, P. *et al.* (2020) ‘Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies’, *J Biol Regul Homeost Agents*, 34(2), p. 1.

Control, E. C. for D. P. and (2021) *SARS-CoV-2 variants of concern as of 8 July 2021*. Available at: <https://www.ecdc.europa.eu/en/covid-19/variants-concern>.

Corman, V. M. *et al.* (2016) ‘Link of a ubiquitous human coronavirus to dromedary camels’, *Proceedings of the National Academy of Sciences*, 113(35), pp. 9864–9869.

Demir, A. B. *et al.* (2020) ‘Identification of the nucleotide substitutions in 62 SARS-CoV-2 sequences from Turkey’, *Turkish Journal of Biology*, 44(SI-1), pp. 178–184.

Dey, A. *et al.* (2020) ‘COVID-19: Scientific Overview of the global Pandemic’, *New Microbes and New Infections*, p. 100800.

Van Dijk, E. L., Jaszczyszyn, Y. and Thermes, C. (2014) ‘Library preparation methods for next-generation sequencing: tone down the bias’, *Experimental cell research*, 322(1), pp. 12–20.

Du, L. *et al.* (2009) ‘The spike protein of SARS-CoV—a target for vaccine and therapeutic development’, *Nature Reviews Microbiology*, 7(3), pp. 226–236.

Duffy, S. (2018) ‘Why are RNA virus mutation rates so damn high?’, *PLoS biology*, 16(8), p. e3000003.

Elizondo, V. *et al.* (2021) ‘SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay’, *Emerging microbes & infections*, 10(1), pp. 51–65.

Fabre, A.-L. *et al.* (2014) ‘An efficient method for long-term room temperature storage of RNA’, *European Journal of Human Genetics*, 22(3), pp. 379–385.

Fang, S. *et al.* (2021) ‘GESS: a database of global evaluation of SARS-CoV-2/hCoV-19 sequences’, *Nucleic acids research*, 49(D1), pp. D706–D714.

Fernández-Naranjo, R. P. *et al.* (2021) 'Statistical data driven approach of COVID-19 in Ecuador: R0 and Rt estimation via new method', *Infectious Disease Modelling*, 6, pp. 232–243. doi: 10.1016/j.idm.2020.12.012.

Focosi, D. and Maggi, F. (2021) 'Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines', *Reviews in Medical Virology*.

Forster, P. *et al.* (2020) 'Phylogenetic network analysis of SARS-CoV-2 genomes', *Proceedings of the National Academy of Sciences*, 117(17), pp. 9241–9243.

Frazier, L. E. *et al.* (2021) 'Spike protein cleavage-activation mediated by the SARS-CoV-2 P681R mutation: a case-study from its first appearance in variant of interest (VOI) A. 23.1 identified in Uganda', *bioRxiv*.

Fu, L. *et al.* (2020) 'Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis', *Journal of Infection*, 80(6), pp. 656–665.

Gaunt, E. R. *et al.* (2010) 'Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method', *Journal of clinical microbiology*, 48(8), pp. 2940–2947.

Gibson, N. J. (2006) 'The use of real-time PCR methods in DNA sequence variation analysis', *Clinica Chimica Acta*, 363(1–2), pp. 32–47.

GISAID (2021) *No Title, Genomic epidemiology of novel coronavirus - Global subsampling.* Available at: <https://www.gisaid.org/phylogenomics/global/nextstrain/>.

Grabowski, F. *et al.* (2021) 'SARS-CoV-2 variant of concern 202012/01 has about twofold replicative advantage and acquires concerning mutations', *Viruses*, 13(3), p. 392.

Grabowski, F., Kochańczyk, M. and Lipniacki, T. (no date) 'L18F Substrain of SARS-CoV-2 VOC-202012/01 Is Rapidly Spreading in England. medRxiv 2021', *Google Scholar*.

Groves, D. C., Rowland-Jones, S. L. and Angyal, A. (2021) 'The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design', *Biochemical and biophysical research communications*, 538, pp. 104–107.

Guan, W. *et al.* (2020) 'Clinical characteristics of coronavirus disease 2019 in China', *New England journal of medicine*, 382(18), pp. 1708–1720.

Han, M. S. *et al.* (2021) 'RT-PCR for SARS-CoV-2: quantitative versus qualitative', *The Lancet Infectious Diseases*, 21(2), p. 165.

Harvey, W. T. *et al.* (2021) 'SARS-CoV-2 variants, spike mutations and immune escape', *Nature Reviews Microbiology*, 19(7), pp. 409–424.

Hoffmann, M. *et al.* (2020) 'SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor', *cell*, 181(2), pp. 271–280.

Hu, B. *et al.* (2015) 'Bat origin of human coronaviruses', *Virology journal*, 12(1), pp. 1–10.

Hu, B. *et al.* (2020) 'Characteristics of SARS-CoV-2 and COVID-19', *Nature Reviews Microbiology*, pp. 1–14.

Hu, B., Huang, S. and Yin, L. (2021) 'The cytokine storm and COVID-19', *Journal of medical virology*, 93(1), pp. 250–256.

Hu, X. *et al.* (2012) 'pIRS: Profile-based Illumina pair-end reads simulator', *Bioinformatics*, 28(11), pp. 1533–1535.

Hussain, A. *et al.* (2020) 'Novel COVID-19: A comprehensive review of transmission, manifestation, and pathogenesis', *Cureus*, 12(5).

Huynh, J. *et al.* (2012) 'Evidence supporting a zoonotic origin of human coronavirus strain NL63', *Journal of virology*, 86(23), pp. 12816–12825.

Isabel, S. *et al.* (2020) 'Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide', *Scientific reports*, 10(1), pp. 1–9.

Kampf, G. *et al.* (2020) 'Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents', *Journal of hospital infection*, 104(3), pp. 246–251.

Kampf, G. (2020) 'Potential role of inanimate surfaces for the spread of coronaviruses and their inactivation with disinfectant agents', *Infection Prevention in Practice*, 2(2), p. 100044.

Kankia, B. I. and Marky, L. A. (1999) 'DNA, RNA, and DNA/RNA oligomer duplexes: A comparative study of their stability, heat, hydration, and Mg²⁺ binding properties', *The Journal of Physical Chemistry B*, 103(41), pp. 8759–8767.

Kaye, A. D. *et al.* (2020) 'Economic Impact of COVID-19 Pandemic on Health Care Facilities and Systems: International Perspectives', *Best Practice & Research Clinical Anaesthesiology*.

Kemp, S. A. *et al.* (2020) 'Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation', *MedRxiv*.

Korber, B. *et al.* (2020) 'Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus', *Cell*, 182(4), pp. 812–827.

Koyama, T., Platt, D. and Parida, L. (2020) 'Variant analysis of SARS-CoV-2 genomes', *Bulletin of the World Health Organization*, 98(7), p. 495.

Lauer, S. A. *et al.* (2020) 'The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application', *Annals of internal medicine*, 172(9), pp. 577–582.

Leung, K. *et al.* (2020) 'First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment', *The Lancet*, 395(10233), pp. 1382–1393. doi: 10.1016/S0140-6736(20)30746-7.

Li, F. *et al.* (2005) 'Structure of SARS coronavirus spike receptor-binding domain complexed with receptor', *Science*, 309(5742), pp. 1864–1868.

Lin, M. *et al.* (2020) 'Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions', *Drug discovery today*.

Liu, P. *et al.* (2020) 'Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?', *PLoS Pathogens*, 16(5), p. e1008421.

Liu, X. and Harada, S. (2013) 'RNA isolation from mammalian samples', *Current protocols in molecular biology*, 103(1), pp. 4–16.

Liu, Y.-C., Kuo, R.-L. and Shih, S.-R. (2020) 'COVID-19: The first documented coronavirus pandemic in history', *Biomedical journal*, 43(4), pp. 328–333.

Liu, Y. *et al.* (2020) 'The reproductive number of COVID-19 is higher compared to SARS coronavirus', *Journal of Travel Medicine*, 27(2), pp. 1–4. doi: 10.1093/jtm/taaa021.

Lodish, H. and Zipursky, S. L. (2001) 'Molecular cell biology', *Biochem Mol Biol Educ*, 29, pp. 126–133.

Looi, M. K. (2020) 'Covid-19: Is a second wave hitting Europe?', *The BMJ*, 371, p. 4113. doi: 10.1136/bmj.m4113.

Louis, D. (no date) 'Temporal signal of nCoV-2019 based on 30 genomes'.

Lubinski, B. *et al.* (2021) 'Functional evaluation of proteolytic activation for the SARS-CoV-2 variant B. 1.1. 7: role of the P681H mutation', *bioRxiv*.

Mansbach, R. A. *et al.* (2021) 'The SARS-CoV-2 spike variant D614G favors an

open conformational state', *Science advances*, 7(16), p. eabf3671.

Mardis, E. and McCombie, W. R. (2017) 'Library quantification: fluorometric quantitation of double-stranded or single-stranded DNA samples using the qubit system', *Cold Spring Harbor Protocols*, 2017(6), p. pdb-prot094730.

Maria, N. *et al.* (2020) 'The socio-economic implications of the coronavirus pandemic (COVID-19): A review', *International Journal of Surgery*, 78, pp. 185–193.

McKee, D. L. *et al.* (2020) 'Candidate drugs against SARS-CoV-2 and COVID-19', *Pharmacological research*, p. 104859.

Menter, T. *et al.* (2020) 'Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction', *Histopathology*, 77(2), pp. 198–209.

Mercatelli, D. *et al.* (2021) 'Coronapp: A web application to annotate and monitor SARS-CoV-2 mutations', *Journal of Medical Virology*, 93(5), pp. 3238–3245.

Mercatelli, D. and Giorgi, F. M. (2020) 'Geographic and genomic distribution of SARS-CoV-2 mutations', *Frontiers in microbiology*, 11, p. 1800.

Mizumoto, K. *et al.* (2020) 'Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020', *Eurosurveillance*, 25(10), p. 2000180.

Mohamed, K. *et al.* (2021) 'Computational drug discovery and repurposing for the treatment of COVID-19: a systematic review', *Bioorganic chemistry*, 106, p. 104490.

Nelson-Sathi, S. *et al.* (2020) 'Structural and functional implications of non-synonymous mutations in the spike protein of 2,954 SARS-CoV-2 genomes', *BioRxiv*.

Nexstrain (2021) *No Title, Genomic epidemiology of novel coronavirus - Global subsampling*. Available at: <https://nextstrain.org/ncov/gisaid/global>.

Nicola, M. *et al.* (2020) 'Evidence based management guideline for the COVID-19 pandemic-Review article', *International Journal of Surgery*.

O'Neill, M. *et al.* (2011) 'Comparison of the TLDA with the Nanodrop and the reference Qubit system', in *Journal of Physics: Conference Series*. IOP Publishing, p. 12047.

of the International, C. S. G. (2020) 'The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-

2', *Nature microbiology*, 5(4), p. 536.

Organization, W. H. (2020) *Estimating mortality from COVID-19: scientific brief*, 4 August 2020. World Health Organization.

Ou, X. *et al.* (2020) 'Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV', *Nature communications*, 11(1), pp. 1–12.

Peacock, T. P. *et al.* (2021) 'The SARS-CoV-2 variants associated with infections in India, B. 1.617, show enhanced spike cleavage by furin', *bioRxiv*.

Perez-Saez, J. *et al.* (2021) 'Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland', *The Lancet Infectious Diseases*, 21(4), pp. e69–e70.

Pfefferle, S. *et al.* (2009) 'Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana', *Emerging infectious diseases*, 15(9), p. 1377.

Phan, T. (2020) 'Genetic diversity and evolution of SARS-CoV-2', *Infection, genetics and evolution*, 81, p. 104260.

Probes, M. (2015) 'Qubit® RNA HS Assay Kits (Q32852, Q32855; Rev A.0)', *Manual*, (February), pp. 1–10.

Proprietary, I. (2020) 'Illumina RNA Prep with Enrichment, (L) Tagmentation Checklist', (August), pp. 1–5.

QIAGEN (2020) 'QIAamp Viral RNA Mini Handbook', (July), pp. 26–29. Available at: <http://www.google.de/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0C CIQFjAA&url=http%3A%2F%2Fwww.qiagen.com%2Fresources%2Fdownload.aspx%3Fid%3Dc80685c0-4103-49ea-aa72-8989420e3018%26lang%3Den&ei=DAEdVdyjHMafPZmDgWA&usg=AFQjCNE5vbTQc8ZGRg1yr4EJw-IVqQgYYw&b>

Ranjan, R., Sharma, A. and Verma, M. K. (2021) 'Characterization of the Second Wave of COVID-19 in India', *medRxiv*.

RI, K. (2020) 'Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19)', *Kemenkes RI*, 0–115.

Rothe, C. *et al.* (2020) 'Transmission of 2019-nCoV infection from an asymptomatic contact in Germany', *New England journal of medicine*, 382(10), pp. 970–971.

Rutledge, R. G. (2004) 'Sigmoidal curve-fitting redefines quantitative real-time PCR with the prospective of developing automated high-throughput applications', *Nucleic acids research*, 32(22), pp. e178–e178.

Sahoo, J. P., Mishra, A. P. and Samal, K. C. (2021) 'Triple Mutant Bengal Strain (B. 1.618) of Coronavirus and the Worst COVID Outbreak in India', *Biotica Research Today*, 3(4), pp. 261–265.

Saito, A. *et al.* (2021) 'SARS-CoV-2 spike P681R mutation enhances and accelerates viral fusion', *bioRxiv*.

Salehi, Z. and Najafi, M. (2014) 'RNA preservation and stabilization', *Biochem Physiol*, 3(126), p. 2.

Senatore, V. *et al.* (2021) 'Indoor versus outdoor transmission of SARS-COV-2: environmental factors in virus spread and underestimated sources of risk', *Euro-Mediterranean Journal for Environmental Integration*, 6(1), pp. 1–9.

Shang, J. *et al.* (2020) 'Cell entry mechanisms of SARS-CoV-2', *Proceedings of the National Academy of Sciences*, 117(21), pp. 11727–11734.

Shehadul Islam, M., Aryasomayajula, A. and Selvaganapathy, P. R. (2017) 'A review on macroscale and microscale cell lysis methods', *Micromachines*, 8(3), p. 83.

Sofi, M. S., Hamid, A. and Bhat, S. U. (2020) 'SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment', *Biosafety and Health*, 2, pp. 217–225. doi: 10.1016/j.bsheal.2020.11.002.

Song, H.-D. *et al.* (2005) 'Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human', *Proceedings of the National Academy of Sciences*, 102(7), pp. 2430–2435.

Stringhini, S. *et al.* (2020) 'Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study', *The Lancet*, 396(10247), pp. 313–319.

Strzelecki, A. (2020) 'The second worldwide wave of interest in coronavirus since the COVID-19 outbreaks in South Korea, Italy and Iran: A Google Trends study', *Brain, behavior, and immunity*, 88, p. 950.

Thomson, E. C. *et al.* (2021) 'Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity', *Cell*, 184(5), pp. 1171–1187.

Udvardi, M. K., Czechowski, T. and Scheible, W.-R. (2008) 'Eleven golden rules of quantitative RT-PCR', *The Plant Cell*, 20(7), pp. 1736–1737.

Velasco, J. M. *et al.* (2020) 'Coding-complete genome sequences of 23 SARS-CoV-2 samples from the Philippines', *Microbiology Resource Announcements*, 9(43), pp. e01031-20.

Vijgen, L. *et al.* (2005) 'Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event', *Journal of virology*, 79(3), pp. 1595–1604.

Voss, W. N. *et al.* (2020) 'Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes in COVID-19 convalescent plasma', *BioRxiv*.

Wacker, M. J. and Godard, M. P. (2005) 'Analysis of one-step and two-step real-time RT-PCR using SuperScript III', *Journal of biomolecular techniques: JBT*, 16(3), p. 266.

Walls, A. C. *et al.* (2020) 'Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein', *Cell*, 181(2), pp. 281–292.

Wan, Y. *et al.* (2020) 'Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus', *Journal of virology*, 94(7).

Wang, D. *et al.* (2020) 'Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China', *Jama*, 323(11), pp. 1061–1069.

Wang, Q. *et al.* (2014) 'Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26', *Cell host & microbe*, 16(3), pp. 328–337.

Wong, J. *et al.* (2020) 'High proportion of asymptomatic and presymptomatic COVID-19 infections in air passengers to Brunei', *Journal of travel medicine*, 27(5), p. taaa066.

Woo, P. C. Y. *et al.* (2012) 'Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavi', *Journal of virology*, 86(7), pp. 3995–4008.

World Health Organization (2020) 'Public Health Emergency of International Concern (PHEIC)', *Who*, pp. 1–10.

World Health Organization (2021a) *Rolling updates on coronavirus disease (COVID-19)*, *Who*. Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>.

World Health Organization (2021b) *WHO Corona Virus (COVID19) Dashboard*. Available at: <https://covid19.who.int/table>.

Wu, J. *et al.* (2021) 'The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom', *Frontiers in Immunology*, 12, p. 2205.

Wu, J. T., Leung, K. and Leung, G. M. (2020) 'Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study', *The Lancet*, 395(10225), pp. 689–697.

Wu, K. *et al.* (2012) 'Mechanisms of host receptor adaptation by severe acute respiratory syndrome coronavirus', *Journal of Biological Chemistry*, 287(12), pp. 8904–8911.

Xu, X. *et al.* (2020) 'Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission', *Science China Life Sciences*, 63(3), pp. 457–460.

Yang, R., Gui, X. and Xiong, Y. (2020) 'Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China', *JAMA network open*, 3(5), pp. e2010182–e2010182.

Yurkovetskiy, L. *et al.* (2020) 'SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain', *BioRxiv*.

Zekri, A. R. N. *et al.* (2021) 'Genomic characterization of SARS-CoV-2 in Egypt', *Journal of Advanced Research*, 30(xxxx), pp. 123–132. doi: 10.1016/j.jare.2020.11.012.

Zhang, H. *et al.* (2020) 'Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19', *Annals of internal medicine*, 172(9), pp. 629–632.

Zhang, J. *et al.* (2021) 'Structural impact on SARS-CoV-2 spike protein by D614G substitution', *Science*, 372(6541), pp. 525–530.

Zhou, P. *et al.* (2020) 'A pneumonia outbreak associated with a new coronavirus of probable bat origin', *nature*, 579(7798), pp. 270–273.

Zhou, W. *et al.* (2020) 'N439K variant in spike protein may alter the infection efficiency and antigenicity of SARS-CoV-2 based on molecular dynamics simulation', *BioRxiv*.

Zimmermann, P. and Curtis, N. (2020) 'Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children', *The Pediatric infectious disease journal*, 39(5), p. 355.

Zou, L. *et al.* (2020) 'SARS-CoV-2 viral load in upper respiratory specimens of

infected patients', *New England Journal of Medicine*, 382(12), pp. 1177–1179.

